Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Status:
RECRUITING
Trial end date:
2027-12-06
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.